NCT07902518Recruiting
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
The Use of Theta-Burst Transcranial Magnetic Stimulation in the Treatment of Persistent Auditory Hallucinations: A Pilot Study
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether theta-burst transcranial magnetic stimulation (TBS), a non-invasive brain stimulation technique, can help reduce persistent auditory verbal hallucinations (hearing voices) in adults with psychotic disorders who have not responded adequately to antipsychotic medications. The main questions it aims to answer are: * Does theta-burst stimulation reduce the severity of auditory verbal hallucinations? * Does theta-burst stimulation improve other psychiatric symptoms, including depressive symptoms and insight into illness? * How well do participants tolerate this treatment, and what side effects do they experience? All participants will receive active theta-burst stimulation. There is no placebo or comparison group. Participants will: * Complete an initial assessment of their mental health, symptoms, and medical history. * Receive 20 brain stimulation sessions over two consecutive weeks, with two sessions per day on weekdays. * Complete follow-up assessments approximately one week and one month after treatment to evaluate changes in symptoms and overall functioning. * Report any side effects experienced during treatment and follow-up.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 22 Oct 2026
- Start date
- 10 Sept 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Diseases
- Schizophrenia
- NCT number
- NCT07902518
What you commit to
- Study type: Interventional
- Planned participants: 12
- From 10 Sept 2025 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Substance use disorder within the previous six months.
- Electroconvulsive therapy (ECT) within the previous six months.
Other illness
- History of epilepsy or seizures.
- Neurological disorders that may interfere with the study or increase the risks associated with transcranial magnetic stimulation.
Other
- Any other contraindication to transcranial magnetic stimulation.
Who the study is looking for
- Adults aged 18 years or older.
- Diagnosis of a schizophrenia-spectrum disorder or bipolar disorder with psychotic symptoms.
- Presence of persistent auditory verbal hallucinations with persecutory content.
- Auditory verbal hallucinations s that have not responded to ≥2 antipsychotic trials, each lasting more than 6 weeks, with daily chlorpromazine-equivalent doses of ≥600 mg and ≥80% of doses taken.
- Stable pharmacological treatment for at least two months before enrollment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut universitaire en santé mentale de Montréal Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.